New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
07:20 EDTMNK, QCORMallinckrodt shares pressured on lingering Acthar concerns, says Jefferies
Jefferies says shares of Mallinckrodt (MNK) sold off yesterday despite "significant accretion potential" from the Questcor (QCOR) acquisition due to lingering Acthar concerns relating to generic competition and the ongoing U.S. Attorney's investigation. The firm says its accretion math suggests $3 in earnings per share by FY15, which it feels justifies a $75-$85 share range for Mallinckrodt. It keeps a Buy rating on the stock with a $77 price target.
News For MNK;QCOR From The Last 14 Days
Check below for free stories on MNK;QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:30 EDTMNKCRT Capital to hold a conference
2nd Annual Investor Conference to be held in Greenwich, CT on September 16.
September 4, 2014
09:02 EDTMNKMallinckrodt announces MNK-155 Phase 3 efficacy trial met primary endpoint
Mallinckrodt reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy. This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014 on September 2-6. In addition to the Phase 3 study, Mallinckrodt will present data at PAINWeek from several other MNK-155 trials, including the pharmacokinetics, safety and subjective effects of abuse-related characteristics.
September 3, 2014
09:07 EDTMNKMallinckrodt reported MNK-155 HAL study data
Subscribe for More Information
07:53 EDTMNKMallinckrodt management to meet with Deutsche Bank
Meeting to be held in New York on September 3 hosted by Deutsche Bank.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use